Sino Biopharmaceutical Ltd. / LaNova Medicines Ltd.

Oncology (multiple solid tumors)

2.0M US cases/yr · $268.0B Global oncology drug sales (2024, IQVIA) · $14.0B Merck upfront + milestones for LM-299 (Nov 2024)

Disease Overview

LaNova Medicines' portfolio targets multiple solid tumor indications spanning non-small cell lung cancer (NSCLC), gastric cancer, biliary tract cancer, breast cancer, and other advanced malignancies where PD-(L)1 checkpoint inhibitors, antibody-drug conjugates (ADCs), and next-generation bispecifics are reshaping standard of care. Solid tumors collectively account for the vast majority of global cancer incidence and mortality, with immuno-oncology and ADC modalities driving the largest share of oncology R&D investment and business development activity since 2020. The PD-1/VEGF bispecific class in particular has become the most contested frontier in IO following Summit Therapeutics' ivonescimab readouts in NSCLC, triggering a wave of licensing and M&A activity among Chinese biotechs with similar assets. China-origin oncology assets have become the dominant source of novel clinical-stage molecules licensed by global pharma, accounting for roughly one-third of in-licensed oncology candidates in 2024 per DealForma/Stifel. LaNova's asset base — one PD-1/VEGF bispecific already licensed to Merck, three clinical ADCs, and ~20 preclinical programs — positions the target squarely in the highest-value oncology modality classes.

Competitive Landscape

The competitive landscape for PD-1/VEGF bispecifics is anchored by Summit Therapeutics' ivonescimab (licensed from Akeso), which produced PFS superiority vs pembrolizumab (Keytruda, Merck) in HARMONi-2 NSCLC. Merck's in-licensed LM-299 from LaNova is the direct response and is now the core strategic IO asset in Merck's late-pipeline bridge post-Keytruda LOE. Other PD-1/VEGF or PD-L1/VEGF bispecifics in development include BioNTech/Biotheus BNT327 (PM8002), Instil Bio/ImmuneOnco IMM2510, and Pfizer's PD-1/VEGF bispecific via its Nona Biosciences licensing. In ADCs, the broader LaNova platform competes with AstraZeneca/Daiichi Sankyo (Enhertu [trastuzumab deruxtecan], datopotamab deruxtecan), Pfizer/Seagen (Padcev [enfortumab vedotin]), Merck/Kelun-Biotech, and Gilead (Trodelvy [sacituzumab govitecan]). LM-108 (anti-CCR8) sits in a crowded emerging class alongside Bristol Myers Squibb's BMS-986340, Gilead/Jounce GS-1811, and Bayer's BAY 3375968. Sino Biopharm's acquisition consolidates a China-origin oncology platform inside a domestic strategic, a defensive move against continued out-licensing to US pharma.